|
gptkbp:instanceOf
|
gptkb:drug
antiretroviral therapy
|
|
gptkbp:approvalYear
|
2021
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
J05AX27
|
|
gptkbp:CASNumber
|
1051375-10-0
|
|
gptkbp:chemicalFormula
|
pyridine derivative
|
|
gptkbp:developedBy
|
gptkb:ViiV_Healthcare
|
|
gptkbp:drugClass
|
protease inhibitor
|
|
gptkbp:eliminationHalfLife
|
~40 days (injection)
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C19H17F2N3O5
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
cabotegravir
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:marketedAs
|
gptkb:Vocabria
gptkb:Apretude
|
|
gptkbp:mechanismOfAction
|
inhibits HIV integrase
|
|
gptkbp:metabolism
|
liver (UGT1A1, UGT1A9)
|
|
gptkbp:pregnancyCategory
|
unknown
|
|
gptkbp:proteinBinding
|
~99%
|
|
gptkbp:relatedTo
|
gptkb:dolutegravir
|
|
gptkbp:routeOfAdministration
|
oral
intramuscular injection
|
|
gptkbp:sideEffect
|
fever
nausea
fatigue
headache
injection site reactions
|
|
gptkbp:usedFor
|
HIV prevention
HIV treatment
|
|
gptkbp:bfsParent
|
gptkb:INSTIs
gptkb:pre-exposure_prophylaxis_(PrEP)
|
|
gptkbp:bfsLayer
|
5
|